ArticleInternational journal of nanomedicine2025
Gallic Acid-Modified Graphene Oxide Nanocomposites Based Photothermal-Chemotherapy Enhancing Melanoma Immunotherapy.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Conventional therapy for the treatment of melanoma often results in poor therapeutic efficacy, and long-term and systemic administration of cancer chemotherapy is accompanied by unpredictable side effects. Graphene oxide (GO)-based photothermal therapy (PTT) combined with chemotherapy has emerged as a rapid and immunogenic alternative, where near-infrared (NIR) irradiation triggers localized hyperthermia via tumor-targeting photothermal immunomodulatory nanomaterials. However, pristine GO nanosheets tend to aggregate under physiological conditions, compromising their photothermal performance. This study aims to develop a combinatorial regimen integrating GO-enhanced photothermal immunotherapy with chemotherapy for synergistic melanoma treatment. Methods: We fabricated a novel photothermal nanomaterial through gallic acid(GA) modification of GO (GAGO), with comprehensive characterization including UV-Vis spectroscopy, FTIR, XRD, and TEM to verify successful synthesis. The photothermal conversion efficiency was systematically evaluated, along with an investigation of the combined therapeutic efficacy and underlying mechanisms of GAGO with paclitaxel for melanoma treatment. Results: In this study, GAGO was developed as a novel photothermal nanomaterial with enhanced dispersibility, superior stability, and reduced biotoxicity, which significantly improved the photothermal conversion efficiency of pristine GO. The synergistic combination of GA-GO-mediated photothermal therapy and paclitaxel chemotherapy effectively activated immune cells and potentiated T cell-mediated antitumor immunity, ultimately achieving remarkable tumor growth suppression. Conclusion: We construct a synergistic platform of photothermal therapy, immunotherapy and chemotherapy, which provides a promising strategy for effective melanoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.